These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 9698094

  • 1. Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine.
    Gao WY, Zhou BS, Johns DG, Mitsuya H, Yen Y.
    Biochem Pharmacol; 1998 Jul 01; 56(1):105-12. PubMed ID: 9698094
    [Abstract] [Full Text] [Related]

  • 2. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus.
    Johns DG, Gao WY.
    Biochem Pharmacol; 1998 May 15; 55(10):1551-6. PubMed ID: 9633990
    [Abstract] [Full Text] [Related]

  • 3. Reversion of hydroxyurea resistance, decline in ribonucleotide reductase activity, and loss of M2 gene amplification.
    McClarty GA, Chan AK, Choy BK, Wright JA.
    Biochem Biophys Res Commun; 1987 Jun 30; 145(3):1276-82. PubMed ID: 3300645
    [Abstract] [Full Text] [Related]

  • 4. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.
    Gao WY, Johns DG, Chokekuchai S, Mitsuya H.
    Proc Natl Acad Sci U S A; 1995 Aug 29; 92(18):8333-7. PubMed ID: 7667290
    [Abstract] [Full Text] [Related]

  • 5. Effect of cyclic AMP on the cell cycle regulation of ribonucleotide reductase M2 subunit messenger RNA concentrations in wild-type and mutant S49 T lymphoma cells.
    Albert DA, Nodzenski E, Yim G, Kowalski J.
    J Cell Physiol; 1990 May 29; 143(2):251-6. PubMed ID: 2159014
    [Abstract] [Full Text] [Related]

  • 6. Molecular and cellular characterization of drug resistant hamster cell lines with alterations in ribonucleotide reductase.
    Tagger AY, Wright JA.
    Int J Cancer; 1988 Nov 15; 42(5):760-6. PubMed ID: 3053467
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea.
    Chitambar CR, Matthaeus WG, Antholine WE, Graff K, O'Brien WJ.
    Blood; 1988 Dec 15; 72(6):1930-6. PubMed ID: 3058232
    [Abstract] [Full Text] [Related]

  • 8. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro.
    Giacca M, Borella S, Calderazzo F, Bianchi LC, D'Agaro P, Rampazzo C, Bianchi V, Reichard P.
    AIDS Res Hum Retroviruses; 1996 May 20; 12(8):677-82. PubMed ID: 8744578
    [Abstract] [Full Text] [Related]

  • 9. Hydroxyurea: mechanisms of HIV-1 inhibition.
    Lori F, Lisziewicz J.
    Antivir Ther; 1998 May 20; 3 Suppl 4():25-33. PubMed ID: 10723506
    [Abstract] [Full Text] [Related]

  • 10. Correlation between levels of ferritin and the iron-containing component of ribonucleotide reductase in hydroxyurea-sensitive, -resistant, and -revertant cell lines.
    Hurta RA, Wright JA.
    Biochem Cell Biol; 1991 Sep 20; 69(9):635-42. PubMed ID: 1793565
    [Abstract] [Full Text] [Related]

  • 11. Deoxyribonucleotide metabolism and cyclic AMP resistance in hydroxyurea-resistant S49 T-lymphoma cells.
    Albert DA, Gudas LJ, Nodzenski E.
    J Cell Physiol; 1987 Feb 20; 130(2):262-9. PubMed ID: 3029148
    [Abstract] [Full Text] [Related]

  • 12. Deoxyadenosine toxicity and cell cycle arrest in hydroxyurea-resistant S49 T-lymphoma cells.
    Albert DA, Nodzenski E.
    Exp Cell Res; 1988 Dec 20; 179(2):417-28. PubMed ID: 3056732
    [Abstract] [Full Text] [Related]

  • 13. Interferon augments the cytotoxicity of hydroxyurea without enhancing its activity against the M2 subunit of ribonucleotide reductase: effects in wild-type and resistant human colon cancer cells.
    Wadler S, Horowitz R, Rao J, Mao X, Schlesinger K, Schwartz EL.
    Cancer Chemother Pharmacol; 1996 Dec 20; 38(6):522-8. PubMed ID: 8823493
    [Abstract] [Full Text] [Related]

  • 14. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations.
    Choy BK, McClarty GA, Chan AK, Thelander L, Wright JA.
    Cancer Res; 1988 Apr 15; 48(8):2029-35. PubMed ID: 2832057
    [Abstract] [Full Text] [Related]

  • 15. Amplification of the genes for both components of ribonucleotide reductase in hydroxyurea resistant mammalian cells.
    Hurta RA, Wright JA.
    Biochem Biophys Res Commun; 1990 Feb 28; 167(1):258-64. PubMed ID: 2178608
    [Abstract] [Full Text] [Related]

  • 16. Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis.
    Wright JA, Chan AK, Choy BK, Hurta RA, McClarty GA, Tagger AY.
    Biochem Cell Biol; 1990 Dec 28; 68(12):1364-71. PubMed ID: 2085432
    [Abstract] [Full Text] [Related]

  • 17. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
    Lori F, Lisziewicz J.
    Clin Infect Dis; 2000 Jun 28; 30 Suppl 2():S193-7. PubMed ID: 10860905
    [Abstract] [Full Text] [Related]

  • 18. Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells.
    Wadler S, Horowitz R, Zhang HY, Schwartz EL.
    Biochem Pharmacol; 1998 May 01; 55(9):1353-60. PubMed ID: 10076525
    [Abstract] [Full Text] [Related]

  • 19. Hydroxyurea for HIV infection.
    Zachary KC, Davis B.
    AIDS Clin Care; 1998 Apr 01; 10(4):25-6, 32. PubMed ID: 11365149
    [Abstract] [Full Text] [Related]

  • 20. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.
    Gao WY, Johns DG, Mitsuya H.
    Mol Pharmacol; 1994 Oct 01; 46(4):767-72. PubMed ID: 7969058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.